E.02 Safety and Efficacy of ETX101, an Investigational AAV9-based Gene Therapy for SCN1A+ Dravet Syndrome: Results from the POLARIS Phase 1/2 Clinical Trials

Monday, December 7, 2026 at 8:30 AM to 10:45 AM · 2 hr. 15 min. (America/Denver)
Platform

Information

Session ID
PLATE26
Presentation Id
3530615
Event ID
24056
Session Type
Presentation